Business Insider5d
GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.40. The company’s shares opened today ...
Business Insider5d
GlaxoSmithKline (GSK) Gets a Hold from UBS
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s shares opened today at p1,435.00. Leverage the ...
Reuters5d
GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK's Q4 EPS and sales beat estimates Shares jump 6% R&D investment to focus on speciality medicines Feb 5 (Reuters) - GSK (GSK.L), opens new tab launched a 2 billion pounds ($2.5 billion) share ...
AZ Central4d
Arizona says GlaxoSmithKline's greed endangered kids with asthma
The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...
European markets open mixed ahead of more earnings reports; GSK up 6%
European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.
London South East2d
Glaxosmithkline Share Chat (GSK)
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...
Insider Monkey4d
Why GSK plc (GSK) Went Up on Wednesday
In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...
Yahoo Finance5d
GSK launches $2.5 billion buyback, lifts sales target after stellar Q4
(Reuters) -GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs ...
London Evening Standard5d
GSK lifts long-term sales targets on new drug pipeline
It came as the boss of the London-listed firm cheered an ‘excellent’ performance in 2024. GSK has increased its long-term sales guidance amid hopes for a boost from new speciality medicines ...
pharmaphorum6d
GlaxoSmithKline pleads guilty in biggest healthcare fraud case in U.S. history
GlaxoSmithKline, one of the world’s largest healthcare and pharmaceutical companies, has announced it will pay US$ 3 billion in order to settle a U.S. scandal over drug fraud. Under the terms of ...
The Motley Fool UK3d
Down 15% and with a P/E below 9! Is the GSK share price still in deep value territory?
Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run. Is there scope for more growth? The content of this article is ...